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Abstract: Uveal melanoma is one of the most deadly diseases in ophthalmology for which 
markers able to predict the appearance of metastasis are needed. The study investigates the 
role of circulating tumor cells (CTC) as a prognostic factor in this disease. We report the 
detection of circulating tumor cells by Isolation by Size of Epithelial Tumor cells (ISET) in 
a cohort of 31 uveal melanoma patients: we identified single CTCs or clusters of cells in  
17 patients, while the control population, subjects with choroidal nevi, showed no CTC in 
peripheral blood. The presence of CTCs did not correlate with any clinical and pathological 
parameter, such as tumor larger basal diameter (LBD), tumor height and TNM. By 
stratifying patients in groups on the basis of the number of CTC (lower or higher than  
10 CTC per 10 mL blood) and the presence of CTC clusters we found a significant 
difference in LBD (p = 0.019), Tumor height (p = 0.048), disease-free and overall survival 
(p < 0.05). In conclusion, we confirm the role of CTC as a negative prognostic marker in 
uveal melanoma patients after a long follow-up period. Further characterization of CTC 
will help understanding uveal melanoma metastasization and improve patient management. 
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1. Introduction 
Uveal melanoma is the most common primary tumor of the eye and is one of the most deadly 
diseases in ophthalmology [1]. It can affect any part of the uveal tract, but choroidal melanoma is 
predominant (86.3%), while iris and ciliary body melanomas are far less frequent [2].  
Despite dramatic improvement in the diagnosis and treatment of the primary tumor the survival rate 
of uveal melanoma patients has not improved in the last half century. Numerous clinical and 
histopathological features have been investigated in order to predict uveal melanoma prognosis. Size 
of tumor is one of the most important clinical features for predicting prognosis of uveal melanoma. 
Increasing tumor thickness, as well as increasing largest basal tumor diameter carries increased risk for 
metastases [3]. 
Notwithstanding the improvement in characterization of the primary tumor, an effective tumor 
marker able to predict the appearance of metastatic disease is still not available [4]. The most likely 
explanation for this is that distant metastases result from tumor cells dissemination through the blood 
stream even before the disease becomes clinically evident [5].  
For this reason the investigation of circulating tumor cells (CTC), which might have the potential to 
colonize certain organs and to give rise to clinically manifest metastatic disease, would be of great 
importance for the understanding of the metastatic process [6]. 
The detection of CTC is particularly cumbersome and technically demanding, but it would be of 
great help to achieve early diagnosis, as well as to evaluate the risk of development of distant metastases 
and to predict relapse [7]. 
Several methods are available to isolate and count CTC in the bloodstream. Some of them directly 
detect the tumor cells present into the circulation, while others rely on the detection of particular 
tumor-specific biomarkers to indirectly detect tumor cell presence.  
In a previous paper [8] we studied a group of 41 patients affected by uveal melanoma including 
small, medium and large size tumors (Collaborative Ocular Melanoma [9]) followed for a period of up 
to 55 months. The study was performed by RT-qPCR for the measurement of tyrosinase mRNA in 
blood as a means to detect and indirectly quantify the number of CTC. On the other hand methods 
aimed at isolating circulating tumor cells from blood samples can provide direct evidence of tumor cell 
presence in blood and allow cell counting and characterization. To reach this object it is possible to 
choose among a variety of different assays relying on several principles. Those based on filtration have 
the advantage of avoiding cell selection due to the immunomagnetic capture procedures often included 
in assay methods for CTC detection. The use of a filtration procedure allows CTC detection based on 
the bigger dimension of tumor-deriving cells in respect to white blood cells. The technique is easy to 
perform and doesn’t require expensive equipment. On the other hand, extensive and qualified work is 
required to verify the presence of CTC on filters and for their further immunohistochemical 
characterization, mainly assigned to an expert anatomo-pathologist.  
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The object of the present paper is the detection of circulating tumor cells by Isolation by Size of 
Epithelial Tumor cells (ISET) in a larger cohort of uveal melanoma patients. The results were 
correlated to the main clinical parameters and to the survival of the tumor patients. 
2. Results and Discussion 
2.1. Detection of Circulating Uveal Melanoma Cells by ISET 
CTC identification was achieved by morphological analysis. As previously reported [10], 
morphological criteria for the identification of circulating melanoma cells included: (i) cell size ≥16 µm, 
(ii) nucleo-cytoplasmic ratio ≥50%, (iii) irregular nuclear shape, (iv) hyperchromatic nucleus, and (v) 
basophilic cytoplasm. Leukocytes were also retained on the membrane in a low percentage, often 
trapped within the pore lumina. Such cells were easily identified due to their smaller size and peculiar 
nuclear morphology. Superposition of cells or cells and pores, nude nuclei, or excess of staining were 
regarded as artifacts. 
CTC were not detected in the control group represented by ten subjects showing ocular lesion 
related to choroidal nevi. Likewise, in 14/31 patients we did not indentify any CTC, while 17/31 (55%) 
subjects showed CTC on filters (Figure 1). In a subgroup of CTC-positive patients (8/17 corresponding 
to 47%), tumor cells were observed both in single units and in microemboli or clusters of cells (CTM) 
(Figure 1).  
For immunohistochemical characterization, CTC isolated on filter were submitted to analysis with 
anti-S100 protein, MART-1, or tyrosinase antibody identifying circulating melanoma cells as weakly 
(tyrosinase) to moderately (MART-1) and strongly (S100) stained cells (Figure 2). In the nine patients 
without CTM, CTC number varied from 2 to 50 CTC/10 mL blood with a median value of 8 CTC/10 
mL blood. The presence of CTM prevented the pathologist from performing an accurate counting of 
the cells circulating in the blood. 
Figure 1. ISET-positive samples display microemboli (A–C) and isolated melanoma cells 
(D) on filters stained with haematoxylin and eosin. 
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Figure 2. Immunohistochemical analysis of circulating tumor microemboli with S-100, 
tyrosinase and Mart-1/Melan A antibodies identifying circulating melanoma cells. 
 
2.2. Correlation of CTC Number and CTM with Tumor Characteristics 
Considering patients for the presence or absence of CTC in peripheral blood, no significant 
correlation was shown between CTC positivity and the main clinico-pathological parameters, 
including tumor larger basal diameter (LBD), tumor height and TNM (see Table 1). 
Table 1. Case study characteristics and their association with CTC presence in uveal 
melanomas. This table reports the number of CTC-positive and CTC-negative cases according 
to patients’ clinico-pathological prognostic parameters.  
Parameters 
All patients  
(n = 31) 
CTC Positive 
(n = 17) 
CTC Negative  
(n = 14) 
p value  
CTC
+
 vs. CTC
−
 
Age (years) 
median 72 72 74 0.564 a 
min-max 52–89 52–82 54–89  
Sex 
Female 14 7 7 0.725 b 
Male 17 10 7  
LBD (mm) 
median 10.0 9.8 9.7 0.691 a 
min-max 3.0–23.4 3.0–23.4 5.6–20.0  
<14.0 mm 24 12 12 0.412 b 
>14.0 mm 7 5 2  
Tumor Height (mm) 
median 4.2 3.5 4.35 0.796 a 
min-max 1.8–13.5 1.8–13.0 2.2–13.5  
<7.0 mm 23 12 11 0.698 b 
>7.0 mm 8 5 3  
TNM 
T1N0M0 7 4  3 0.557 b 
T2N0M0 17 8 9  
T3N0M0 4 3 1  
T4N0M0 1 0 1  
T1N0M1 1 1 0  
T4N0M1 1 1 0  
a: Mann-Whitney; b:Chi-square test. 
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Patients’ stratification according to the absolute CTC number identified three categories 
characterized by CTC numbers lower or higher than 10 CTC/10 mL blood and by the presence of 
microemboli. The adopted cut-off value of for patients’ stratification derives from the analytical 
procedure which enables the simultaneous filtration of ten 1 mL-aliquots of blood with a reported 
sensitivity of 1 cell/mL [11]. A statistically significant difference was found in the distribution based on 
LBD (p = 0.019; Table 2) and tumor height (p = 0.048; Table 3). 
In the nine patients without CTM, the number of CTC was significantly correlated to LBD  
(Pearson’s correlation coefficient R = 0.823, p = 0.006) and Tumor Height (Pearson’s correlation 
coefficient R = 0.774, p = 0.014) (Figure 3). 
Table 2. Correlation of CTC count with lager basal diameter LBD. 
LBD (mm) <10 CTC/10 mL blood >10 CTC/10 mL blood CTM Total 
<14.0 mm 17 1 6 24 
>14.0 mm 2 3 2 7 
Total 19 4 8 31 
Chi-square test p = 0.019. 
Table 3. Correlation of CTC count with tumor height. 
Tumor Height (mm) <10 CTC/10 mL blood >10 CTC/10 mL blood CTM Total- 
<7.0 mm 16 1 6 23 
>7.0 mm 3 3 2 8 
Total 19 4 8 31 
Chi-square test p = 0.048. 
Figure 3. Linear regression analysis between CTC count and lager basal diameter LBD (A) 
and tumor height (B). 
 
2.3. Correlation of CTC Number and CTM with Patients’ Survival 
The evaluation of the impact of CTC positivity on the survival of the patients with uveal melanoma 
was performed by univariate analysis. Patients were categorized into two groups: (i) subjects with less than 
10 CTC/10 mL of blood; (ii) subjects with more than 10 CTC/10 mL of blood and CTM. Kaplan-Meier 
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curves calculated for the two groups evidence a significantly different disease-free survival (Log Rank 
test p = 0.012) and overall survival (Log Rank test p = 0.017) as illustrated in Figure 4.  
Figure 4. Kaplan-Meier curves for disease free (A) and overall survival (B) in the whole 
case study. 
 
2.4. Discussion 
Herein we report the feasibility of a filtration based method (ISET, isolation by size of epithelial 
tumor cells) to detect CTC and CTM in uveal melanoma patients. The filtration method was previously 
employed in our laboratory for CTC detection in breast cancer [12], in cutaneous melanoma  
patients [10] as well as in patients affected by adrenocortical carcinomas [13] demonstrating to 
represent a valid approach for CTC detection in any kind of tumor, irrespective of the expression of 
tumor-specific markers. 
In this study CTC analysis was performed in uveal melanomas with a follow up time of several 
years from the diagnosis and on patients showing ocular lesions related to choroidal nevi, included in 
the study as the control group. We verified the expected absence of CTC in the control population, 
while, in our cohort of uveal melanoma patients, we identified 17 CTC-positive subjects with a high 
percentage (8/17) exhibiting CTC aggregates on filters. As demonstrated by other authors [14], the 
possibility that CTM might be an artifact caused by sample manipulation can be excluded taking also 
into account that all clinical specimens were processed identically and CTM were observed only in a 
subset of samples. CTM are thought to have higher metastatic potential compared to that of isolated 
CTC [15]. Moreover, the absence of proliferating and of apoptotic cells within CTM supports the 
hypothesis of a survival advantage for this cells as well as of a theoretical increased chemoresistance in 
comparison to single proliferating CTC. It is presumable that CTM differ from isolated CTC also in 
the mechanism of detachment from the primary tumor resulting from a ―collective migration‖ [14]. 
Similarly to what recently reported by Suesskind and coworkers [6], we could no evidence any 
significant relationship between CTC presence (CTC-negative versus CTC-positive samples) and 
patients (sex, age) or tumor characteristics (LBD, Tumor height, TNM). Nevertheless the 84% of 
patients with less than 10 CTC/10 mL blood showed LBD < 14 mm, while 3/4 patients (75%) with 
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CTC number higher than 10 had larger diameter. The same distribution could be evidenced when 
analyzing samples on the basis of tumor height. Moreover, a significant correlation between CTC count 
and both LBD and Tumor height could be evidenced in the nine CTC-positive patients without CTM. 
Interestingly, considering the positivity rate calculated on the basis of tumor stage classification, it is 
evident that ISET could detect a higher rate of CTC positivity in T1 and T2 stages in comparison to 
Ulmer and coworkers’ results [16] corresponding to an overall lower frequency of CTC detection (see 
Table 1). 
The evaluation of the impact of CTC positivity on the survival of the patients with uveal melanoma 
showed that CTC-negative patients as well as positive patients with less than 1 CTC per mL of blood 
showed a better disease free and overall survival than patients with more than 1 CTC per mL of blood, 
including those demonstrating CTM. Our results confirm the findings of a recent paper [17] reporting a 
strong association of CTC count with progression-free and overall survival.  
3. Experimental 
3.1. Patients and Sample Collection 
Thirty-one patients with uveal melanoma, consecutively examined at the Eye Clinic, Department of 
Oto-neuro-ophthalmology University of Florence, Italy, were enrolled in the study. Patients’ characteristics 
are reported in Table 1. The study was approved by the Institutional Review Board and an informed 
consensus was obtained from all patients. 
Peripheral blood samples for the isolation of circulating tumor cells by the ISET method were 
obtained either at diagnosis, at the time of therapy or at subsequent outpatient visit. All patients were 
treated for the primary ocular lesion with surgery (enucleation) or radiotherapy (brachitherapy with I
125
 
or proton beam therapy). Four patients had been treated with proton beam, at diagnosis, in a different 
Hospital and submitted to blood sampling after 2–5 years from the diagnosis when they were visited at 
the Eye Clinic in Florence for the periodic control. 
Absence of metastatic melanoma at the time of blood sampling was confirmed by clinical 
evaluation, routine biochemistry (i.e., liver enzymes, and lactate dehydrogenase levels), and liver 
ultrasonography in all patients except two. As the control group, 10 patients showing ocular lesion 
related to choroidal nevi were enrolled. For ISET, 10 mL of blood were collected in EDTA tubes and 
processed within 4 h.  
3.2. Isolation by Size of Epithelial Tumor Cells (ISET) 
Blood samples from 31 uveal melanoma patients were collected and submitted to ISET. ISET was 
carried out using a modification of a previously described [10] module of filtration kindly provided by 
ScreenCell company (Paris, France) and a disposable filtration block (ISET Metablock, ScreenCell) 
containing a membrane with calibrated 8-μm diameter pores. The module of filtration has 10  
spot-compartments making it possible to load and filter 10 individual samples in parallel. Peripheral 
blood (8–10 mL) from patients with uveal melanoma was collected on buffered EDTA, diluted 1:10 
with the ISET Metabuffer
®
 (ScreenCell), incubated for 10 min at room temperature, and filtered. Ten 
milliliter of diluted solution, corresponding to 1 mL of undiluted blood, was loaded into each 
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compartment and filtered by controlled aspiration under vacuum (0.1 Bar). The membrane was then 
washed once with phosphate-buffered saline (PBS), disassembled from the filtration module, and 
allowed to air-dry.  
3.3. Cell Staining and Immunostaining 
After rehydration with PBS, the spots obtained on the filter, each one corresponding to 1 mL of 
filtered blood, were stained with haematoxylin and eosin. Hematoxylin S (Merck KGaA, 64271 
Darmstadt, Germany) was applied to the membrane for 1 min, followed by 1% eosin Y (Thermo 
Electron Corporation, Thermo Fisher Scientific Inc., Waltham, MA, USA) for 45 s.  
For immunostaining the whole Metafilter was hydrated with Tris Buffered Saline (TBS, pH 7.4). 
Having removed the white part of Metafilter, the filter was rinsed with TBS for one minute, the excess 
of TBS was removed with the absorbing paper and the Metafilter was put on the paraffin film in a 
humid chamber. Each spot was incubated for 5 min at room temperature with 70 µL of permeabilized 
buffer: in each immunostaining step, we covered the spots with a coverslip 20 × 20 mm to contain the 
liquid. The filter was washed quickly in a bath containing distilled water and incubated for 1 h on each 
spot with 70 µL Polyclonal anti-human S-100 Protein Antibody (Dako, Glostrup, Denmark) diluted 
1:100 in Antibody Diluent (Ventana Medical Systems, Tucson, AZ, USA). The Metafilter was washed 
one time with wash buffer for one minute and put again in a bath containing distilled water. Staining 
was achieved treating the spots with 70 µL EnVision™ Detection System, Peroxidase/DAB, (Dako) 
for 40 min at room temperature followed by 3,3'-diaminobenzidine (Dako) for 10 min at room 
temperature as chromogen. Then the Metafilter has been placed on the horizontal surface (a paraffin 
film) and the cells nuclei were slightly counterstained with Mayer’s hematoxylin for 6 min. Finally the 
spots were rinsed with running water, dried for 10 min at room temperature and mounted on slide with 
Faramount Aqueous mounting medium. 
3.4. Statistical Analysis 
Statistical analysis of the results was carried out using the SPSS software package, release 20.0.1 
(SPSS INC, Chicago, IL, USA). Statistical differences between groups were assessed using Chi-square 
test for discontinuous variables and Mann-Whitney test for the continuous ones. p values <0.05 were 
considered statistically significant. The cumulative survival probability in various subgroups was 
calculated using the Kaplan-Meier life tables and differences assessed with the log rank method. 
4. Conclusions  
In conclusion, here we confirm the role of CTC as a negative prognostic marker in uveal melanoma 
patients after a long follow-up period, up to 15 years after diagnosis. Further characterization of CTC, 
also at the molecular level, will help understanding uveal melanoma metastatic process and improving 
patients’ management. Other molecular markers can be investigated in the view of a non-invasive 
monitoring of disease progression in this pathology characterized by long survival time. 
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